Selected research
Industry Research
Diagnostic Nuclear Drug Industry Research Report 2026
Market perspective
The global Diagnostic Nuclear Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Diagnostic Nuclear Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Diagnostic Nuclear Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Diagnostic Nuclear Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Diagnostic Nuclear Drug include Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, SIEMENS, Dongcheng and Eli Lilly, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Diagnostic Nuclear Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Diagnostic Nuclear Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Diagnostic Nuclear Drug Market by Company
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
SIEMENS
Dongcheng
Eli Lilly
Novartis
China Isotope & Radiation
Diagnostic Nuclear Drug Segment by Type
Tc-99m
F-18
Other
Diagnostic Nuclear Drug Segment by Application
Oncology
Cardiology
Other
Diagnostic Nuclear Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Nuclear Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Nuclear Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Nuclear Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Diagnostic Nuclear Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tc-99m
- F-18
- Other
Applications
- Oncology
- Cardiology
- Other
Companies covered
- Bracco Imaging
- Cardinal Health
- Curium Pharma
- GE Healthcare
- Jubilant Pharma
- Lantheus
- SIEMENS
- Dongcheng
- Eli Lilly
- Novartis
- China Isotope & Radiation
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Diagnostic Nuclear Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tc-99m
- 2.2.3 F-18
- 2.2.4 Other
- 2.3 Diagnostic Nuclear Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oncology
- 2.3.3 Cardiology
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Diagnostic Nuclear Drug Breakdown Data by Type
- 3.1 Global Diagnostic Nuclear Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Diagnostic Nuclear Drug Forecasted Market Size by Type (2027-2032)
4 Diagnostic Nuclear Drug Breakdown Data by Application
- 4.1 Global Diagnostic Nuclear Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Diagnostic Nuclear Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Diagnostic Nuclear Drug Market Perspective (2021-2032)
- 5.2 Global Diagnostic Nuclear Drug Growth Trends by Region
- 5.2.1 Global Diagnostic Nuclear Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Diagnostic Nuclear Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Diagnostic Nuclear Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Diagnostic Nuclear Drug Market Dynamics
- 5.3.1 Diagnostic Nuclear Drug Industry Trends
- 5.3.2 Diagnostic Nuclear Drug Market Drivers
- 5.3.3 Diagnostic Nuclear Drug Market Challenges
- 5.3.4 Diagnostic Nuclear Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Diagnostic Nuclear Drug Players by Revenue
- 6.1.1 Global Top Diagnostic Nuclear Drug Players by Revenue (2021-2026)
- 6.1.2 Global Diagnostic Nuclear Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Diagnostic Nuclear Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Diagnostic Nuclear Drug Head Office and Area Served
- 6.4 Global Diagnostic Nuclear Drug Players, Product Type & Application
- 6.5 Global Diagnostic Nuclear Drug Manufacturers Established Date
- 6.6 Global Diagnostic Nuclear Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Diagnostic Nuclear Drug Market Size (2021-2032)
- 7.2 North America Diagnostic Nuclear Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Diagnostic Nuclear Drug Market Size by Country (2021-2026)
- 7.4 North America Diagnostic Nuclear Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Diagnostic Nuclear Drug Market Size (2021-2032)
- 8.2 Europe Diagnostic Nuclear Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Diagnostic Nuclear Drug Market Size by Country (2021-2026)
- 8.4 Europe Diagnostic Nuclear Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Diagnostic Nuclear Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Diagnostic Nuclear Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Diagnostic Nuclear Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Diagnostic Nuclear Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Diagnostic Nuclear Drug Market Size (2021-2032)
- 10.2 South America Diagnostic Nuclear Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Diagnostic Nuclear Drug Market Size by Country (2021-2026)
- 10.4 South America Diagnostic Nuclear Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Diagnostic Nuclear Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Diagnostic Nuclear Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Diagnostic Nuclear Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Diagnostic Nuclear Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Bracco Imaging
- 12.1.1 Bracco Imaging Company Information
- 12.1.2 Bracco Imaging Business Overview
- 12.1.3 Bracco Imaging Revenue in Diagnostic Nuclear Drug Business (2021-2026)
- 12.1.4 Bracco Imaging Diagnostic Nuclear Drug Product Portfolio
- 12.1.5 Bracco Imaging Recent Developments
- 12.2 Cardinal Health
- 12.2.1 Cardinal Health Company Information
- 12.2.2 Cardinal Health Business Overview
- 12.2.3 Cardinal Health Revenue in Diagnostic Nuclear Drug Business (2021-2026)
- 12.2.4 Cardinal Health Diagnostic Nuclear Drug Product Portfolio
- 12.2.5 Cardinal Health Recent Developments
- 12.3 Curium Pharma
- 12.3.1 Curium Pharma Company Information
- 12.3.2 Curium Pharma Business Overview
- 12.3.3 Curium Pharma Revenue in Diagnostic Nuclear Drug Business (2021-2026)
- 12.3.4 Curium Pharma Diagnostic Nuclear Drug Product Portfolio
- 12.3.5 Curium Pharma Recent Developments
- 12.4 GE Healthcare
- 12.4.1 GE Healthcare Company Information
- 12.4.2 GE Healthcare Business Overview
- 12.4.3 GE Healthcare Revenue in Diagnostic Nuclear Drug Business (2021-2026)
- 12.4.4 GE Healthcare Diagnostic Nuclear Drug Product Portfolio
- 12.4.5 GE Healthcare Recent Developments
- 12.5 Jubilant Pharma
- 12.5.1 Jubilant Pharma Company Information
- 12.5.2 Jubilant Pharma Business Overview
- 12.5.3 Jubilant Pharma Revenue in Diagnostic Nuclear Drug Business (2021-2026)
- 12.5.4 Jubilant Pharma Diagnostic Nuclear Drug Product Portfolio
- 12.5.5 Jubilant Pharma Recent Developments
- 12.6 Lantheus
- 12.6.1 Lantheus Company Information
- 12.6.2 Lantheus Business Overview
- 12.6.3 Lantheus Revenue in Diagnostic Nuclear Drug Business (2021-2026)
- 12.6.4 Lantheus Diagnostic Nuclear Drug Product Portfolio
- 12.6.5 Lantheus Recent Developments
- 12.7 SIEMENS
- 12.7.1 SIEMENS Company Information
- 12.7.2 SIEMENS Business Overview
- 12.7.3 SIEMENS Revenue in Diagnostic Nuclear Drug Business (2021-2026)
- 12.7.4 SIEMENS Diagnostic Nuclear Drug Product Portfolio
- 12.7.5 SIEMENS Recent Developments
- 12.8 Dongcheng
- 12.8.1 Dongcheng Company Information
- 12.8.2 Dongcheng Business Overview
- 12.8.3 Dongcheng Revenue in Diagnostic Nuclear Drug Business (2021-2026)
- 12.8.4 Dongcheng Diagnostic Nuclear Drug Product Portfolio
- 12.8.5 Dongcheng Recent Developments
- 12.9 Eli Lilly
- 12.9.1 Eli Lilly Company Information
- 12.9.2 Eli Lilly Business Overview
- 12.9.3 Eli Lilly Revenue in Diagnostic Nuclear Drug Business (2021-2026)
- 12.9.4 Eli Lilly Diagnostic Nuclear Drug Product Portfolio
- 12.9.5 Eli Lilly Recent Developments
- 12.10 Novartis
- 12.10.1 Novartis Company Information
- 12.10.2 Novartis Business Overview
- 12.10.3 Novartis Revenue in Diagnostic Nuclear Drug Business (2021-2026)
- 12.10.4 Novartis Diagnostic Nuclear Drug Product Portfolio
- 12.10.5 Novartis Recent Developments
- 12.11 China Isotope & Radiation
- 12.11.1 China Isotope & Radiation Company Information
- 12.11.2 China Isotope & Radiation Business Overview
- 12.11.3 China Isotope & Radiation Revenue in Diagnostic Nuclear Drug Business (2021-2026)
- 12.11.4 China Isotope & Radiation Diagnostic Nuclear Drug Product Portfolio
- 12.11.5 China Isotope & Radiation Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst